Can genomic testing help my husband avoid chemotherapy?

Question

Hello doctor,

I would like some clarification regarding my husband’s recent breast cancer diagnosis and the role of genetic testing in treatment decisions.

My husband is 38 years old and was diagnosed last month with stage 2 breast cancer, which we understand is relatively uncommon in men. His biopsy showed that the tumor is ER-positive and HER2-negative. He is otherwise healthy, with no history of diabetes, heart disease, or other major medical conditions.

The tumor has already been surgically removed, and his oncologist is now recommending genomic testing, specifically Oncotype DX. His BRCA test results are also still pending.

We are trying to better understand:

How can genomic testing performed after the tumor has already been removed help determine whether chemotherapy is needed?
Does Oncotype DX genuinely influence chemotherapy decisions in cases like this, or could it unnecessarily delay treatment?
How reliable is this type of testing in predicting recurrence?
Could the pending BRCA results also affect the treatment plan, particularly the type or duration of hormone therapy recommended after surgery?

We would really appreciate a clearer explanation of how these tests guide treatment decisions and whether they are considered important in this situation.

Please help.

Answer 1

Hello,

Welcome to icliniq.com.

I understand this has been an overwhelming and emotional time for both of you, especially because breast cancer in men is relatively uncommon. However, there are several reassuring aspects in your husband’s case.

The fact that breast cancer was detected at stage 2 is important because it means the disease is still considered potentially curable, and treatment outcomes are often very good when managed appropriately.

In addition, ER-positive (estrogen receptor-positive), HER2-negative (human epidermal growth factor receptor 2-negative) breast cancers are usually quite responsive to hormonal therapy, which gives us effective long-term treatment options.

Regarding the genomic testing, such as Oncotype DX (a genomic test that analyzes the activity of 21 genes in early-stage breast cancer tissue to predict the likelihood of recurrence and determine if chemotherapy will be beneficial), this is not simply an additional or unnecessary step. It is a very useful tool that helps oncologists better understand the biological behavior of the tumor after surgery.

Even though the tumor has already been removed, the preserved tumor tissue can still be analyzed to estimate:

The risk of cancer recurrence.
How likely the cancer is to benefit from chemotherapy.
Whether hormonal therapy alone may be sufficient.

In some patients, the genomic test shows that the expected benefit from chemotherapy is very small, allowing them to safely avoid chemotherapy and its side effects. In others, the test may show a higher recurrence risk, meaning chemotherapy would likely provide meaningful benefit. For this reason, the test can genuinely influence treatment decisions and help personalize therapy rather than applying the same treatment approach to everyone.

The waiting period for genomic testing is usually considered acceptable and is commonly built into modern breast cancer treatment planning.

Your husband’s pending BRCA (breast cancer gene) results are also important. A positive BRCA mutation can sometimes influence:

Long-term surveillance strategies.
Family screening recommendations.
The choice of certain targeted therapies in specific situations.
Surgical considerations in some patients.

Hormonal therapy will remain a key part of treatment for ER-positive disease, but BRCA status may influence the broader treatment strategy and follow-up planning.

In addition to medical treatment, emotional support from family plays a major role in recovery and coping during this period. He needs to understand that this is a treatable condition and that many patients with early-stage breast cancer do very well with modern therapy.

Maintaining good nutrition, hydration, physical activity as tolerated, and regular follow-up with the oncology team will also help support his recovery during treatment.

As for investigations, it is recommended:

Genomic testing (such as Oncotype DX).
BRCA genetic testing follow-up and interpretation.

Possible treatment plan:

Hormonal therapy.
Chemotherapy only if genomic testing indicates a significant benefit.
Regular oncology follow-up and supportive care.

I hope this answers your query.

Please let me know if I can help you further.

Thank you.